Tip os
Log ind
Claus Christiansen.jpg
Foto: Jyllands-Posten

Biotech investor sets his sights on fibrosis

Top picks in English:

Biotech investor Claus Christiansen believes drugs to treat fibrosis will represent a huge market in the near future. His company Nordic Biosciences has discovered a biomarker that can predict the spread of lung fibrosis.


BY LONNI LYNGE
Offentliggjort 19.05.15 kl. 11:10

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Leo Pharma invests in US biotech company

Leo_Pharma_20100615_TH_0701.jpg Top picks in English:

The Danish dermatology company Leo Pharma has pumped money into a US based biotech company developing a medical device mainly to be used in treatments of a hair loss disease. It is also the first agreement made from Leo’s newly founded hub in Boston.

Former William Demant CFO joins German rehab giant

Top picks in English:

A former Chief Financial Officer from hearing device maker William Demant takes over as finance chief for one of the biggest rehabilitation care companies in the world.

”It’s professional speed dating for life science”

Top picks in English:

Stockholm is currently hosting the biggest dating event for life science companies in the Nordic countries. A number of Danish players have very clear objectives for the event.

Lundbeck Foundation company goes public

Top picks in English:

Lundbeckfonden Ventures’ portfolio company Bonesupport has listed on the Swedish stock market and raised SEK 500 million (about USD 57 million). The IPO puts a period to a busy half year, where two other companies have been sold. New investments are coming up, says managing partner Mette Kirstine Agger.

Sweden’s Oasmia aims to raise nearly USD 19m

Top picks in English:

The executive board of Oasmia Pharmaceutical has resolved to carry out an issue of shares in order to raise millions for development, production and debt installments.

Novo Seeds launches new biotech company

Top picks in English:

Novo Seeds has teamed up with innovation incubator Borean to inject millions in a “very exciting project”, which the investment company was made aware of by an executive at ALK through a third company. Moreover, they have attracted a foreign profile to the role as chairman.

Forsiden lige nu

Nye fremskridt i løvens biologiske sats

Kim Kjøller LEO Pharma.jpg Medicinal & Biotek:

Biotekselskabet Argenx har klaret sig helskindet igennem det prækliniske arbejde på det stof, som Leo Pharma har investeret i. Næste stop er fase 1. Godt for det biologiske sats, lyder det fra forskningsdirektør Kim Kjøller.

Sklerosemiddel fra Roche reducerer risiko for handicap

Medicinal & Biotek:

Nye resultater fra Roches studier med sklerosemidlet Ocrevus viser positive effekter på patienter, og reducerer risikoen for at blive bundet til en kørestol.

De første studieresultater: Overvægtige taber sig med Novo Nordisks fedmehåb

Medicinal & Biotek:

Novo Nordisk fører an i jagten på at udvikle medicin, som kan smelte kilo af overvægtige kroppe. Spritnye resultater for GLP-1-analogen Semaglutid viser de første gode takter for medicinalkoncernens næste fedmehåb. (opdateret)

Lundbeck-direktør: Jeg var klar over, at FDA så det på en anden måde

Medicinal & Biotek:

Om Lundbeck vil forsøge en tredje gang at få udvidet indlægssedlen på antidepressivet Trintellix i USA er endnu uvist, siger forskningsdirektør Anders Gersel Pedersen for hvem, nattens afslag fra FDA ikke var en fuldstændig overraskelse.

Novo Seeds investerer millioner i potentielt guldæg

Medicinal & Biotek:

Nyt biotekselskab, der udspringer fra Københavns Universitet, har fået 20 mio. kr. fra Novo Seeds til at udvikle lægemiddel til behandling af diabetes, fedme og fedtlever.

Novo står til længe ventet labelopdatering i Europa

Medicinal & Biotek:

Novo Nordisk er godt på vej til at kunne medtage data fra det vigtige hjerte-kar-studie Leader i indlægssedlen for diabetesblockbusteren Victoza i Europa efter en positiv anbefaling fra CHMP.

ANNONCE
ANNONCE


ANNONCE